Biovitrum would like to invite you to a media and investor meeting in Stockholm on Thursday, October 22, in conjunction with the announcement of the Interim Report for the third quarter and first nine month 2009.
The report will be presented by Biovitrum’s CEO Martin Nicklasson and CFO Göran Arvidson. The presentation will be held in English and webcasted.
About Biovitrum
Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For more information please visit www.biovitrum.com
